NurExone Biologic Inc.

NurExone Biologic Inc. is a biopharmaceutical company dedicated to developing regenerative exosome-based therapies for central nervous system (CNS) injuries. The company's mission is to advance regenerative medicine by targeting nerve and tissue regeneration to facilitate recovery from conditions such as spinal cord injury and traumatic brain injury. While its research and development activities are primarily based in Israel, the company maintains its headquarters in Toronto, Canada.

At the core of NurExone's approach is its proprietary ExoTherapy platform, which leverages exosomes as biologically guided nanocarriers to deliver therapeutic compounds. The company's lead product candidate, ExoPTEN, is a nanodrug specifically designed for the treatment of acute spinal cord injuries and optic nerve damage. ExoPTEN functions by utilizing exosomes loaded with a unique siRNA sequence to inhibit the PTEN gene, thereby promoting nerve regeneration and functional recovery. Beyond its primary indications, NurExone is also exploring the platform's potential for other applications, including traumatic brain injury and facial nerve injury. Additionally, the company aims to provide exosome-related solutions and targeted delivery systems to other pharmaceutical entities.

NurExone Biologic has achieved significant regulatory milestones, including the U.S. FDA's Orphan Drug Designation for ExoPTEN in acute spinal cord injury, which offers benefits such as market protection. The company is progressing towards initiating first-in-human clinical trials for ExoPTEN, with expectations for these trials to commence in 2026 or 2027. To bolster its North American operations and manufacturing capabilities, NurExone established Exo-Top Inc., a wholly-owned U.S. subsidiary. Exo-Top plans to develop a commercial exosome production facility in Indianapolis, Indiana. Dr. Lior Shaltiel serves as the Chief Executive Officer and Director. Recent corporate updates include positive financial results for the first quarter of 2026 and the granting of patents in South Korea and Australia related to its ExoPTEN technology and exosome production processes.